Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

Costimulation of T cell responses with monoclonal antibody agonists (mAb-AG) targeting 4-1BB showed robust anti-tumor activity in preclinical models, but their clinical development was hampered by low efficacy (Utomilumab) or severe liver toxicity (Urelumab). Here we show that isotype and intrinsic...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xinyue, Li, Fanlin, Wu, Yi, Cheng, Chen, Han, Ping, Wang, Jieyi, Yang, Xuanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526162/
https://www.ncbi.nlm.nih.gov/pubmed/31105267
http://dx.doi.org/10.1038/s41467-019-10088-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526162/
https://www.ncbi.nlm.nih.gov/pubmed/31105267
http://dx.doi.org/10.1038/s41467-019-10088-1

Ejemplares similares